Pulmonary Fibrosis

Pulmonary Fibrosis – Medical Student Study Guide

Definition

Pulmonary fibrosis refers to a group of chronic interstitial lung diseases characterized by progressive scarring of the pulmonary interstitium, leading to impaired gas exchange, reduced lung compliance, and restrictive ventilatory defects. The prototypical and most important entity for exams and clinical practice is idiopathic pulmonary fibrosis (IPF), a specific chronic fibrosing interstitial pneumonia of unknown cause, occurring primarily in older adults and limited to the lungs with a radiologic or histopathologic pattern of usual interstitial pneumonia (UIP).

Epidemiology

Overall, pulmonary fibrosis is uncommon but increases with age. IPF typically presents between ages 60 and 80 and has a male predominance. Major associated conditions and risk factors across fibrotic ILDs include connective tissue diseases (e.g., rheumatoid arthritis, systemic sclerosis), environmental/occupational exposures (e.g., silica, metal dusts, organic antigens in hypersensitivity pneumonitis), prior radiation therapy, certain drugs (e.g., amiodarone, bleomycin, methotrexate, nitrofurantoin), and genetic predisposition in familial forms. Idiopathic pulmonary fibrosis often follows a progressive course with a median survival of approximately 3–5 years from diagnosis despite treatment, although antifibrotic therapy can slow functional decline. [2](https://pubmed.ncbi.nlm.nih.gov/41309680/)

Pathophysiology

Pulmonary fibrosis reflects chronic, dysregulated repair of the alveolar epithelium following repeated epithelial injury in genetically and environmentally susceptible hosts. Instead of normal restoration of lung architecture, there is abnormal activation of fibroblasts and myofibroblasts, leading to excessive deposition of extracellular matrix (especially collagen) in the interstitium.

In IPF and other fibrotic ILDs, key features include:

• Alveolar epithelial cell injury and apoptosis with disrupted basement membranes.
• Profibrotic signaling, involving cytokines and growth factors such as transforming growth factor-β (TGF-β), platelet-derived growth factor (PDGF), and connective tissue growth factor (CTGF), which promote fibroblast proliferation and matrix deposition.
• Myofibroblast foci that actively synthesize collagen and other matrix proteins, progressively remodeling and thickening the interstitium.
• Architectural distortion of lung parenchyma over time, with loss of normal alveolar units, development of honeycomb cysts, traction bronchiectasis, and reduced capillary bed area.

This fibrotic remodeling decreases lung compliance (stiff lungs), causes restrictive physiology, impairs diffusion capacity, and leads to chronic hypoxemia. Chronic hypoxic vasoconstriction and vascular remodeling may result in secondary pulmonary hypertension and right heart strain. Idiopathic pulmonary fibrosis is a specialty focus of current research and modeling for individualized treatment strategies, particularly in the context of feature-based and machine learning–assisted decision support. [2](https://pubmed.ncbi.nlm.nih.gov/41309680/)

Clinical Presentation

Pulmonary fibrosis usually develops insidiously. Students should recognize the classic constellation of symptoms and signs:

• Symptoms
  • Progressive exertional dyspnea (most common presenting complaint).
  • Nonproductive, persistent cough.
  • Fatigue, decreased exercise tolerance, weight loss in more advanced disease.
  • Pleuritic chest discomfort is less common but may occur.
• Physical examination
  • Bibasilar, end-inspiratory "velcro" crackles.
  • Digital clubbing, especially in IPF and in more advanced fibrotic disease.
  • Tachypnea and use of accessory muscles as disease progresses.
  • Signs of pulmonary hypertension/right heart failure (loud P2, right ventricular heave, peripheral edema) in advanced cases.

Symptoms typically evolve over months to years. Many patients are initially misdiagnosed with asthma, COPD, or recurrent bronchitis, highlighting the importance of auscultation and appropriate imaging. Acute exacerbations can occur, characterized by rapid worsening of dyspnea and new infiltrates on imaging.

Diagnosis

Diagnosis requires integration of history, physical exam, pulmonary function tests, imaging, and often multidisciplinary discussion (pulmonology, radiology, pathology). For IPF in particular, guidelines emphasize a structured approach to distinguish it from other causes of fibrotic interstitial lung disease. [2](https://pubmed.ncbi.nlm.nih.gov/41309680/)

History and clinical evaluation

• Duration and progression of dyspnea and cough.
• Detailed occupational and environmental exposure history (e.g., birds, molds, farming, mining, metal dust).
• Medication history (amiodarone, bleomycin, methotrexate, nitrofurantoin, etc.).
• Smoking history.
• Symptoms or history of connective tissue disease (Raynaud phenomenon, arthritis, skin thickening, rash, myositis).
• Family history of pulmonary fibrosis or early-onset idiopathic interstitial lung disease.

Pulmonary function tests (PFTs)

• Restrictive pattern: reduced FVC and TLC with a normal or increased FEV1/FVC ratio.
• Reduced diffusing capacity for carbon monoxide (DLCO), often early and disproportionately decreased.
• Exercise testing may show exertional oxygen desaturation.

Imaging

• Chest radiograph
  • Reticular or reticulonodular opacities, often basilar and peripheral.
  • Decreased lung volumes.
  • Late disease: honeycombing and architectural distortion.
• High-resolution CT (HRCT) (key diagnostic tool)
  • UIP pattern in IPF: subpleural, basal-predominant reticular abnormality, traction bronchiectasis, and honeycombing with minimal ground-glass opacities.
  • Other ILD patterns (e.g., NSIP, hypersensitivity pneumonitis, sarcoidosis) show different distributions and character of opacities.

Advanced imaging modalities such as ultra-short echo time MRI (UTE-MRI) and ventilation-weighted MRI are being investigated as radiation-free tools to quantify structural and functional impairment in fibrotic lung diseases, although HRCT remains the diagnostic standard in routine practice. [1](https://pubmed.ncbi.nlm.nih.gov/41328895/) [7](https://europepmc.org/article/MED/41635029)

Laboratory and serologic tests

• Autoimmune serologies (ANA, RF, anti-CCP, ENA panel, myositis antibodies) to evaluate for underlying connective tissue disease.
• Routine labs (CBC, CMP) are usually nonspecific but help exclude alternative diagnoses and assess comorbidities.

Bronchoscopy and lung biopsy

• Bronchoscopy with bronchoalveolar lavage (BAL) may help exclude infection or malignancy and suggest alternative ILDs (e.g., lymphocytosis in hypersensitivity pneumonitis).
• Surgical lung biopsy or transbronchial cryobiopsy may be considered when HRCT is not definitive. Histology in UIP shows patchy, temporally heterogeneous fibrosis with fibroblast foci and honeycombing.

Differential diagnosis

• Other interstitial lung diseases (NSIP, hypersensitivity pneumonitis, sarcoidosis, organizing pneumonia).
• Connective tissue disease-associated ILD (e.g., RA-ILD, systemic sclerosis ILD).
• Pneumoconioses (silicosis, asbestosis, coal worker’s pneumoconiosis).
• Drug-induced ILD (amiodarone, bleomycin, etc.).
• Chronic infections and non-cystic fibrosis bronchiectasis with traction changes.

Management

Management goals include slowing disease progression, relieving symptoms, preserving functional capacity, treating comorbidities, and evaluating for lung transplantation when appropriate. Idiopathic pulmonary fibrosis has specific evidence-based antifibrotic therapies, whereas treatment strategies for other fibrotic ILDs are tailored to the underlying cause.

General measures

• Smoking cessation for all patients who smoke.
• Vaccinations: influenza, pneumococcal, COVID-19, and others per guidelines.
• Oxygen therapy for resting or exertional hypoxemia to reduce dyspnea and improve quality of life.
• Pulmonary rehabilitation to improve exercise tolerance, symptoms, and functional status.
• Management of comorbidities: pulmonary hypertension, coronary artery disease, GERD, depression/anxiety, sleep-disordered breathing.

Pharmacologic therapy

• Antifibrotic agents (IPF and some progressive fibrotic ILDs)
  • Pirfenidone: oral antifibrotic with anti-inflammatory and TGF-β–modulating properties; reduces decline in FVC and may improve progression-free survival in IPF.
  • Nintedanib: oral tyrosine kinase inhibitor targeting receptors for VEGF, FGF, and PDGF; slows decline in FVC in IPF and other chronic fibrosing ILDs with a progressive phenotype.
  • Both drugs primarily slow progression rather than reverse established fibrosis and are often considered standard of care for eligible IPF patients.
• Immunosuppressive therapy
  • Used in non-IPF fibrotic ILDs where inflammation plays a larger role (e.g., connective tissue disease–associated ILD, chronic hypersensitivity pneumonitis, some NSIP patterns).
  • Agents may include glucocorticoids, mycophenolate mofetil, azathioprine, cyclophosphamide, or rituximab depending on disease and guideline recommendations.
  • In IPF, chronic immunosuppression has not demonstrated benefit and may be harmful; antifibrotic therapy is preferred.

Emerging strategies leverage computational models and feature-based approaches to support individualized choice and timing of antifibrotic therapy in idiopathic pulmonary fibrosis, reflecting the growing emphasis on precision medicine. [2](https://pubmed.ncbi.nlm.nih.gov/41309680/)

Lung transplantation

• Considered for advanced, progressive disease despite optimal medical therapy.
• Best outcomes occur when referral is made early, before severe deconditioning and multi-organ compromise.
• Age, comorbidities, and psychosocial factors are key determinants of candidacy.

Supportive and palliative care

• Symptom-directed therapy for cough and dyspnea (e.g., antitussives, low-dose opioids in selected patients).
• Psychosocial support and advanced care planning, especially in IPF given its progressive nature.

Key Clinical Pearls

• Think of pulmonary fibrosis in older adults with progressive exertional dyspnea, nonproductive cough, and bibasilar "velcro" crackles on auscultation.
• High-resolution CT is essential to characterize the pattern of interstitial lung disease; a classic UIP pattern in the right clinical context can establish IPF without biopsy.
• Differentiating IPF from other fibrotic ILDs (e.g., connective tissue disease–associated ILD, hypersensitivity pneumonitis) is critical because treatment strategies differ.
• Antifibrotic agents (pirfenidone, nintedanib) slow lung function decline in IPF but do not cure the disease; set realistic expectations with patients.
• Assess for environmental and occupational exposures, drug toxicity, and autoimmune features in every patient with suspected fibrotic ILD.
• Chronic hypoxemia and progressive fibrosis can lead to pulmonary hypertension and right heart failure, which significantly worsen prognosis.
• Early referral to a specialized ILD center and consideration of lung transplantation in appropriate candidates improve access to comprehensive care and advanced therapies.
• Emerging imaging tools such as ultrashort echo time MRI and advanced decision-support models are being studied but have not yet replaced HRCT and standard guideline-based management. [1](https://pubmed.ncbi.nlm.nih.gov/41328895/) [2](https://pubmed.ncbi.nlm.nih.gov/41309680/) [7](https://europepmc.org/article/MED/41635029)